Login Register Cart 0
Review Article

头皮牛皮癣的当代和未来治疗策略综述

卷 25, 期 5, 2024

发表于: 15 March, 2024

页: [353 - 373] 页: 21

弟呕挨: 10.2174/0113894501292755240304063020

价格: $65

摘要

头皮牛皮癣是牛皮癣的一种常见表现，严重影响患者的生活质量。大约80%的牛皮癣病例涉及头皮，使其成为身体最常受影响的区域。头皮牛皮癣的治疗尤其重要，因为它难以治疗的性质和对整体健康的重大不利影响。伴随着身体不适和瘙痒的症状，牛皮癣，特别是当它影响到头皮时，会造成严重的心理伤害。治疗头皮牛皮癣可能是具有挑战性的，由于其位置和相关症状，如脱屑和瘙痒，这就是为什么各种药物已被广泛用于难治性病例。局部治疗，如皮质类固醇和维生素D类似物，通过减少炎症和调节皮肤细胞生长来治疗头皮牛皮癣。焦油基洗发水、水杨酸溶液和保湿剂可以控制结垢。UVB光疗法可以减少炎症。严重者可能需要全身药物治疗，如口服类维生素a和免疫抑制剂。虽然头皮牛皮癣有多种治疗方法，但由于其有限的优势和缺乏评估其有效性的对照研究，引起了人们的关注。考虑到这些挑战，显然需要创新的方法来有效地解决这一问题。最近在局部治疗、光疗、全身药物和补充疗法方面的进展在治疗头皮牛皮癣方面显示出有希望的结果。此外，生物制剂的出现，特别是抗il -17和抗il -23治疗头皮牛皮癣的药物，已经有了显着的改善。这篇综述强调了头皮牛皮癣缺乏耐受性良好和有效的治疗方法，并强调了在这一领域进一步研究的重要性。本综述的目的是澄清目前可用或正在临床试验中研究的治疗头皮牛皮癣的不同治疗方案。

关键词: 头皮牛皮癣，光疗，生活质量，局部治疗，生物治疗，全身治疗。

« Previous
图形摘要

[1]
Daniyal M, Akram M, Zainab R, et al. Progress and prospects in the management of psoriasis and developments in phyto-therapeutic modalities. Dermatol Ther 2019; 32(3)e12866
[http://dx.doi.org/10.1111/dth.12866] [PMID: 30838736]
[2]
Papp K, Berth-Jones J, Kragballe K, Wozel G, De La Brassinne M. Scalp psoriasis: A review of current topical treatment options. J Eur Acad Dermatol Venereol 2007; 21(9): 1151-60.
[http://dx.doi.org/10.1111/j.1468-3083.2007.02424.x] [PMID: 17894698]
[3]
Vincenzi C, Tosti A. Efficacy and tolerability of a shampoo containing broad-spectrum cannabidiol in the treatment of scalp inflammation in patients with mild to moderate scalp psoriasis or seborrheic dermatitis. Skin Appendage Disord 2020; 6(6): 355-61.
[http://dx.doi.org/10.1159/000510896] [PMID: 33313051]
[4]
Iversen L, Conrad C, Eidsmo L, et al. Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIN study. J Eur Acad Dermatol Venereol 2023; 37(5): 1004-16.
[http://dx.doi.org/10.1111/jdv.18846] [PMID: 36606536]
[5]
Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: Results from the population-based multinational assessment of psoriasis and psoriatic arthritis survey. J Am Acad Dermatol 2014; 70(5): 871-881.e30, 30.
[http://dx.doi.org/10.1016/j.jaad.2013.12.018] [PMID: 24576585]
[6]
Blakely K, Gooderham M. Management of scalp psoriasis: Current perspectives. Psoriasis 2016; 6: 33-40. [http://dx.doi.org/10.2147/PTT.S85330].
[PMID: 29387592]
[7]
van de Kerkhof PCM, de Hoop D, de Korte J, Kuipers MV. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology 1998; 197(4): 326-34.
[http://dx.doi.org/10.1159/000018026] [PMID: 9873169]
[8]
Farber EM, Nall L. Natural history and treatment of scalp psoriasis. Cutis 1992; 49(6): 396-400.
[PMID: 1628504]
[9]
Dawber RP, Van Neste D. Hair and Scalp Disorders: Common Presenting Signs, Differential Diagnosis. (2nd ed.). London: CRC Press 2004; p. 17.
[http://dx.doi.org/10.3109/9780203490273]
[10]
Taylor CR, Racette AL. A 308-nm excimer laser for the treatment of scalp psoriasis. Lasers Surg Med 2004; 34(2): 136-40.
[http://dx.doi.org/10.1002/lsm.10218] [PMID: 15004825]
[11]
Mosca M, Hong J, Hadeler E, Brownstone N, Bhutani T, Liao W. Scalp psoriasis: A literature review of effective therapies and updated recommendations for practical management. Dermatol Ther 2021; 11(3): 769-97.
[http://dx.doi.org/10.1007/s13555-021-00521-z] [PMID: 33893995]
[12]
Narcisi A, Valenti M, Cortese A, et al. ANTI-IL17 and ANTI-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study. Dermatol Ther 2022; 35(2)e15228
[http://dx.doi.org/10.1111/dth.15228] [PMID: 34820969]
[13]
Weigle N, McBane S. Psoriasis. Am Fam Physician 2013; 87(9): 626-33.
[PMID: 23668525]
[14]
Ruano J, Suárez-Fariñas M, Shemer A, Oliva M, Guttman-Yassky E, Krueger JG. Molecular and cellular profiling of scalp psoriasis reveals differences and similarities compared to skin psoriasis. PLoS One 2016; 11(2)e0148450
[http://dx.doi.org/10.1371/journal.pone.0148450] [PMID: 26849645]
[15]
Wolk K, Witte E, Wallace E, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: A potential role in psoriasis. Eur J Immunol 2006; 36(5): 1309-23.
[http://dx.doi.org/10.1002/eji.200535503] [PMID: 16619290]
[16]
Narbutt J, Olejniczak I, Sobolewska-Sztychny D, et al. Narrow band ultraviolet B irradiations cause alteration in interleukin-31 serum level in psoriatic patients. Arch Dermatol Res 2013; 305(3): 191-5.
[http://dx.doi.org/10.1007/s00403-012-1293-6] [PMID: 23108364]
[17]
Harvima IT, Nilsson G, Suttle MM, Naukkarinen A. Is there a role for mast cells in psoriasis? Arch Dermatol Res 2008; 300(9): 461-78.
[http://dx.doi.org/10.1007/s00403-008-0874-x] [PMID: 18719932]
[18]
Veal CD, Capon F, Allen MH, et al. Family-based analysis using a dense single-nucleotide polymorphism-based map defines genetic variation at PSORS1, the major psoriasis-susceptibility locus. Am J Hum Genet 2002; 71(3): 554-64.
[http://dx.doi.org/10.1086/342289] [PMID: 12148091]
[19]
Dombek PE, Cue D, Sedgewick J, et al. High-frequency intracellular invasion of epithelial cells by serotype M1 group A streptococci: M1 protein-mediated invasion and cytoskeletal rearrangements. Mol Microbiol 1999; 31(3): 859-70.
[http://dx.doi.org/10.1046/j.1365-2958.1999.01223.x] [PMID: 10048029]
[20]
Hosogi M, Schmelz M, Miyachi Y, Ikoma A. Bradykinin is a potent pruritogen in atopic dermatitis: A switch from pain to itch. Pain 2006; 126(1): 16-23.
[http://dx.doi.org/10.1016/j.pain.2006.06.003] [PMID: 16842920]
[21]
Nakamura M, Toyoda M, Morohashi M. Pruritogenic mediators in psoriasis vulgaris: Comparative evaluation of itch-associated cutaneous factors. Br J Dermatol 2003; 149(4): 718-30.
[http://dx.doi.org/10.1046/j.1365-2133.2003.05586.x] [PMID: 14616362]
[22]
Leon A, Rosen JD, Hashimoto T, Fostini AC, Paus R, Yosipovitch G. Itching for an answer: A review of potential mechanisms of scalp itch in psoriasis. Exp Dermatol 2019; 28(12): 1397-404.
[http://dx.doi.org/10.1111/exd.13947] [PMID: 31022307]
[23]
Werner B, Brenner FM, Böer A. Histopathologic study of scalp psoriasis: Peculiar features including sebaceous gland atrophy. Am J Dermatopathol 2008; 30(2): 93-100.
[http://dx.doi.org/10.1097/DAD.0b013e31816421fd] [PMID: 18360109]
[24]
Poblet E, Jimenez F, Escario-Travesedo E, et al. Eccrine sweat glands associate with the human hair follicle within a defined compartment of dermal white adipose tissue. Br J Dermatol 2018; 178(5): 1163-72.
[http://dx.doi.org/10.1111/bjd.16436] [PMID: 29432654]
[25]
Sugawara K, Bíró T, Tsuruta D, et al. Endocannabinoids limit excessive mast cell maturation and activation in human skin. J Allergy Clin Immunol 2012; 129(3): 726-738.e8.
[http://dx.doi.org/10.1016/j.jaci.2011.11.009] [PMID: 22226549]
[26]
Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 2003; 135(1): 1-8.
[http://dx.doi.org/10.1111/j.1365-2249.2004.02310.x] [PMID: 14678257]
[27]
Chan CS, Van Voorhees AS, Lebwohl MG, et al. Treatment of severe scalp psoriasis: From the medical board of the national psoriasis foundation. J Am Acad Dermatol 2009; 60(6): 962-71.
[http://dx.doi.org/10.1016/j.jaad.2008.11.890] [PMID: 19375191]
[28]
van de Kerkhof PC, Franssen ME. Psoriasis of the scalp. Am J Clin Dermatol 2001; 2(3): 159-65.
[http://dx.doi.org/10.2165/00128071-200102030-00005] [PMID: 11705093]
[29]
Feldman SR, Housman TS. Patients’ vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol 2003; 4(4): 221-4.
[http://dx.doi.org/10.2165/00128071-200304040-00001] [PMID: 12680800]
[30]
Franz TJ, Parsell DA, Halualani RM, et al. Betamethasone valerate foam 0.12%: A novel vehicle with enhanced delivery and efficacy. Int J Dermatol 1999; 38(8): 628-32.
[http://dx.doi.org/10.1046/j.1365-4362.1999.00782.x] [PMID: 10487457]
[31]
van der Vleuten CJM, van de Kerkhof PCM. Management of scalp psoriasis: Guidelines for corticosteroid use in combination treatment. Drugs 2001; 61(11): 1593-8.
[http://dx.doi.org/10.2165/00003495-200161110-00006] [PMID: 11577796]
[32]
Housman TS, Keil KA, Mellen BG, McCarty MA, Fleischer AB Jr, Feldman SR. The use of 0.25% zinc pyrithione spray does not enhance the efficacy of clobetasol propionate 0.05% foam in the treatment of psoriasis. J Am Acad Dermatol 2003; 49(1): 79-82.
[http://dx.doi.org/10.1067/mjd.2003.417] [PMID: 12833013]
[33]
Sintov AC, Yarmolinsky L, Dahan A, Ben-Shabat S. Pharmacological effects of vitamin D and its analogs: Recent developments. Drug Discov Today 2014; 19(11): 1769-74.
[http://dx.doi.org/10.1016/j.drudis.2014.06.008] [PMID: 24947685]
[34]
Barrea L, Savanelli MC, Di Somma C, et al. Vitamin D and its role in psoriasis: An overview of the dermatologist and nutritionist. Rev Endocr Metab Disord 2017; 18(2): 195-205.
[http://dx.doi.org/10.1007/s11154-017-9411-6] [PMID: 28176237]
[35]
Warren RB, Brown BC, Griffiths CEM. Topical treatments for scalp psoriasis. Drugs 2008; 68(16): 2293-302.
[http://dx.doi.org/10.2165/0003495-200868160-00003] [PMID: 18973394]
[36]
Green C, Ganpule M, Harris D, et al. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. Br J Dermatol 1994; 130(4): 483-7.
[http://dx.doi.org/10.1111/j.1365-2133.1994.tb03382.x] [PMID: 8186114]
[37]
Shokeen D, O’Neill JL, Taheri A, Feldman SR. Are topical keratolytic agents needed in the treatment of scalp psoriasis? Dermatol Online J 2014; 20(3)doj_21762
[http://dx.doi.org/10.5070/D3203021762] [PMID: 24656276]
[38]
Langner A, Wolska H, Hebborn P. Treatment of psoriasis of the scalp with coal tar gel and shampoo preparations. Cutis 1983; 32(3): 290-291, 295-296.
[PMID: 6627992]
[39]
Unissa R, Kumar PM, Pasha M, Begum S, Maheswari B. Psoriasis: A comprehensive review. Asian j res pharm sci 2019; 9(1): 29-38.
[http://dx.doi.org/10.5958/2231-5659.2019.00005.5]
[40]
McGill A, Frank A, Emmett N, et al. The antipsoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory competent mitochondria. FASEB J 2005; 19(8): 1012-4.
[http://dx.doi.org/10.1096/fj.04-2664fje] [PMID: 15802490]
[41]
Shemer A, Nathansohn N, Kaplan B, Weiss G, Newman N, Trau H. Treatment of scalp seborrheic dermatitis and psoriasis with an ointment of 40% urea and 1% bifonazole. Int J Dermatol 2000; 39(7): 532-4.
[http://dx.doi.org/10.1046/j.1365-4362.2000.00986-3.x] [PMID: 10940120]
[42]
Mohamed S, Huang BQ, Kechadi MT. Prediction of NB-UVB phototherapy treatment response of psoriasis patients using data mining. 2017 IEEE International Conference on Bioinformatics and Biomedicine (BIBM). Kansas City, MO, USA, 13-16 November 2017, pp. 1067-1071
[http://dx.doi.org/10.1109/BIBM.2017.8217804]
[43]
Almutawa F, Thalib L, Hekman D, Sun Q, Hamzavi I, Lim HW. Efficacy of localized phototherapy and photodynamic therapy for psoriasis: A systematic review and meta-analysis. Photodermatol Photoimmunol Photomed 2015; 31(1): 5-14.
[http://dx.doi.org/10.1111/phpp.12092] [PMID: 24283358]
[44]
Mehta D, Lim HW. Ultraviolet B phototherapy for psoriasis: Review of practical guidelines. Am J Clin Dermatol 2016; 17(2): 125-33.
[http://dx.doi.org/10.1007/s40257-016-0176-6] [PMID: 26872953]
[45]
Lebwohl M, Ali S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001; 45(4): 487-502.
[http://dx.doi.org/10.1067/mjd.2001.117046] [PMID: 11568737]
[46]
Prabhu S, Shenoi SD. Photochemotherapy (PUVA) in psoriasis and vitiligo. Indian J Dermatol Venereol Leprol 2014; 80(6): 497-504.
[http://dx.doi.org/10.4103/0378-6323.144143] [PMID: 25382505]
[47]
Ibbotson SH, Dawe RS, Dinkova-Kostova AT, et al. Glutathione S-transferase genotype is associated with sensitivity to psoralen-ultraviolet A photochemotherapy. Br J Dermatol 2012; 166(2): 380-8.
[http://dx.doi.org/10.1111/j.1365-2133.2011.10661.x] [PMID: 21967523]
[48]
Ibbotson SH, Farr PM. The time-course of psoralen ultraviolet A (PUVA) erythema. J Invest Dermatol 1999; 113(3): 346-9.
[http://dx.doi.org/10.1046/j.1523-1747.1999.00700.x] [PMID: 10469332]
[49]
Lapolla W, Yentzer BA, Bagel J, Halvorson CR, Feldman SR. A review of phototherapy protocols for psoriasis treatment. J Am Acad Dermatol 2011; 64(5): 936-49.
[http://dx.doi.org/10.1016/j.jaad.2009.12.054] [PMID: 21429620]
[50]
Jury CS, McHenry P, Burden AD, Lever R, Bilsland D. Narrowband ultraviolet B (UVB) phototherapy in children. Clin Exp Dermatol 2006; 31(2): 196-9.
[http://dx.doi.org/10.1111/j.1365-2230.2006.02061.x] [PMID: 16487089]
[51]
Yanovsky RL, Huang KP, Buzney EA. Optimizing narrowband UVB phototherapy regimens for psoriasis. Dermatol Clin 2020; 38(1): 1-10.
[http://dx.doi.org/10.1016/j.det.2019.08.001] [PMID: 31753182]
[52]
Menter A, Gelfand JM, Connor C, et al. Joint american academy of dermatology–national psoriasis foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol 2020; 82(6): 1445-86.
[http://dx.doi.org/10.1016/j.jaad.2020.02.044] [PMID: 32119894]
[53]
Hallaji Z, Barzegari M, Balighi K, Mansoori P, Taheri A, Mansoori P. A comparison of three times vs. five times weekly narrowband ultraviolet B phototherapy for the treatment of chronic plaque psoriasis. Photodermatol Photoimmunol Photomed 2010; 26(1): 10-5.
[http://dx.doi.org/10.1111/j.1600-0781.2009.00473.x] [PMID: 20070833]
[54]
Motamedi M, Chehade A, Sanghera R, Grewal P. A clinician’s guide to topical retinoids. J Cutan Med Surg 2022; 26(1): 71-8.
[http://dx.doi.org/10.1177/12034754211035091] [PMID: 34292058]
[55]
Lo Y, Tsai TF. Updates on the treatment of erythrodermic psoriasis. Psoriasis 2021; 11: 59-73.
[http://dx.doi.org/10.2147/PTT.S288345] [PMID: 34136373]
[56]
Kaushik SB, Lebwohl MG. Review of safety and efficacy of approved systemic psoriasis therapies. Int J Dermatol 2019; 58(6): 649-58.
[http://dx.doi.org/10.1111/ijd.14246] [PMID: 30246393]
[57]
Carretero G, Ribera M, Belinchón I, et al. Guidelines for the use of acitretin in psoriasis. Actas Dermo-Sifiliográficas 2013; 104(7): 598-616.
[http://dx.doi.org/10.1016/j.adengl.2013.01.001] [PMID: 23891453]
[58]
Cronstein BN, Aune TM. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol 2020; 16(3): 145-54.
[http://dx.doi.org/10.1038/s41584-020-0373-9] [PMID: 32066940]
[59]
Coates LC, Merola JF, Grieb SM, Mease PJ, Callis Duffin K. Methotrexate in psoriasis and psoriatic arthritis. J Rheumatol 2020; 96: 31-5.
[http://dx.doi.org/10.3899/jrheum.200124] [PMID: 32482765]
[60]
Hamed KM, Dighriri IM, Baomar AF, et al. Overview of methotrexate toxicity: A comprehensive literature review. Cureus 2022; 14(9)e29518
[http://dx.doi.org/10.7759/cureus.29518] [PMID: 36312688]
[61]
Faulds D, Goa KL, Benfield P. Cyclosporin. Drugs 1993; 45(6): 953-1040.
[http://dx.doi.org/10.2165/00003495-199345060-00007] [PMID: 7691501]
[62]
Colombo MD, Cassano N, Bellia G, Vena GA. Cyclosporine regimens in plaque psoriasis: An overview with special emphasis on dose, duration, and old and new treatment approaches. Sci World J 2013; 2013: 805705.
[http://dx.doi.org/10.1155/2013/805705]
[63]
Rosmarin DM, Lebwohl M, Elewski BE, Gottlieb AB. Cyclosporine and psoriasis: 2008 National Psoriasis Foundation consensus conference. J Am Acad Dermatol 2010; 62(5): 838-53.
[http://dx.doi.org/10.1016/j.jaad.2009.05.017] [PMID: 19932926]
[64]
Napolitano M, Megna M, Balato A, et al. Systemic treatment of pediatric psoriasis: A review. Dermatol Ther 2016; 6(2): 125-42.
[http://dx.doi.org/10.1007/s13555-016-0117-6] [PMID: 27085539]
[65]
Al-Janabi A, Yiu ZZN. Biologics in psoriasis: Updated perspectives on long-term safety and risk management. Psoriasis 2022; 12: 1-14.
[http://dx.doi.org/10.2147/PTT.S328575] [PMID: 35024352]
[66]
Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest 1996; 98(8): 1878-87.
[http://dx.doi.org/10.1172/JCI118989] [PMID: 8878440]
[67]
Thaçi D, Unnebrink K, Sundaram M, Sood S, Yamaguchi Y. Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study. J Eur Acad Dermatol Venereol 2015; 29(2): 353-60.
[http://dx.doi.org/10.1111/jdv.12553] [PMID: 24846518]
[68]
Moore A, Gordon KB, Kang S, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 2007; 56(4): 598-603.
[http://dx.doi.org/10.1016/j.jaad.2006.09.002] [PMID: 17113190]
[69]
Iborra M, Beltrán B, Bastida G, Aguas M, Nos P. Infliximab and adalimumab-induced psoriasis in Crohn’s disease: A paradoxical side effect. J Crohn’s Colitis 2011; 5(2): 157-61.
[http://dx.doi.org/10.1016/j.crohns.2010.11.001] [PMID: 21453886]
[70]
Connock M, Tubeuf S, Malottki K, et al. Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis. Health Technol Assess 2010; 14(2) (Suppl. 2): 1-10.
[http://dx.doi.org/10.3310/hta14suppl2-01] [PMID: 21047485]
[71]
Lee A, Scott LJ. Certolizumab pegol: A review in moderate to severe plaque psoriasis. BioDrugs 2020; 34(2): 235-44.
[http://dx.doi.org/10.1007/s40259-020-00416-z] [PMID: 32207094]
[72]
Kokolakis G, Vadstrup K, Hansen JB, Carrascosa JM. Brodalumab is associated with high rates of complete clearance and quality of life improvement: A subgroup analysis of patients with psoriasis and concomitant psoriatic arthritis. Dermatology 2022; 238(4): 620-9.
[http://dx.doi.org/10.1159/000520290] [PMID: 34823247]
[73]
Farahnik B, Beroukhim K, Abrouk M, et al. Brodalumab for the treatment of psoriasis: A review of phase III trials. Dermatol Ther 2016; 6(2): 111-24.
[http://dx.doi.org/10.1007/s13555-016-0121-x] [PMID: 27221323]
[74]
Farahnik B, Beroukhim K, Zhu TH, et al. Ixekizumab for the treatment of psoriasis: A review of phase III trials. Dermatol Ther 2016; 6(1): 25-37.
[http://dx.doi.org/10.1007/s13555-016-0102-0] [PMID: 26910853]
[75]
Ramonda R, Lorenzin M, Carriero A, et al. Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: A 24-month prospective, multicentre study. RMD Open 2021; 7(1)e001519
[http://dx.doi.org/10.1136/rmdopen-2020-001519] [PMID: 33593933]
[76]
Yang EJ, Beck KM, Liao W. Secukinumab in the treatment of psoriasis: Patient selection and perspectives. Psoriasis 2018; 8: 75-82.
[http://dx.doi.org/10.2147/PTT.S146004] [PMID: 30425963]
[77]
Galluzzo M, Tofani L, Lombardo P, et al. Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: A 1 year real-life study. J Clin Med 2020; 9(7): 2170.
[http://dx.doi.org/10.3390/jcm9072170] [PMID: 32659978]
[78]
Nakamura M, Lee K, Jeon C, et al. Guselkumab for the treatment of psoriasis: A review of phase III trials. Dermatol Ther 2017; 7(3): 281-92.
[http://dx.doi.org/10.1007/s13555-017-0187-0] [PMID: 28639011]
[79]
Näslund-Koch C, Zachariae C, Skov L. Tildrakizumab: An evidence-based review of its use in the treatment of moderate-to-severe chronic plaque psoriasis. Ther Clin Risk Manag 2020; 16: 903-16.
[http://dx.doi.org/10.2147/TCRM.S227880] [PMID: 33061395]
[80]
Augustin M, Lambert J, Zema C, et al. Effect of risankizumab on patient-reported outcomes in moderate to severe psoriasis: The UltIMMa-1 and UltIMMa-2 randomized clinical trials. JAMA Dermatol 2020; 156(12): 1344-53.
[http://dx.doi.org/10.1001/jamadermatol.2020.3617] [PMID: 33052382]
[81]
Blair HA. Risankizumab: A review in moderate to severe plaque psoriasis. Drugs 2020; 80(12): 1235-45.
[http://dx.doi.org/10.1007/s40265-020-01357-1] [PMID: 32632826]
[82]
Krulig E, Gordon KB. Ustekinumab: An evidence-based review of its effectiveness in the treatment of psoriasis. Core Evid 2010; 5: 11-22. [https://doi.org/10.2147%2Fce.s5994].
[PMID: 20694136]
[83]
Torres T, Filipe P. Small molecules in the treatment of psoriasis. Drug Dev Res 2015; 76(5): 215-27.
[http://dx.doi.org/10.1002/ddr.21263] [PMID: 26255795]
[84]
Khobzey K, Liskova I, Szegedi A, et al. Effectiveness of adalimumab in the treatment of scalp and nail affection in patients with moderate to severe plaque psoriasis in routine clinical practice. Acta Dermatovenerol Alp Panonica Adriat 2017; 26(1): 11-4. [https://doi.org/10.15570/actaapa.2017.3].
[PMID: 28352929]
[85]
Fotiadou C, Lazaridou E, Sotiriou E, Kyrgidis A, Apalla Z, Ioannides D. Scalp psoriasis and biologic agents: A retrospective, comparative study from a tertiary psoriasis referral centre. J Eur Acad Dermatol Venereol 2016; 30(12): 2091-6.
[http://dx.doi.org/10.1111/jdv.13780] [PMID: 27406435]
[86]
Thaçi D, Ortonne JP, Chimenti S, et al. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. Br J Dermatol 2010; 163(2): 402-11.
[http://dx.doi.org/10.1111/j.1365-2133.2010.09791.x] [PMID: 20377585]
[87]
Mantravadi S, Ogdie A, Kraft WK. Tumor necrosis factor inhibitors in psoriatic arthritis. Expert Rev Clin Pharmacol 2017; 10(8): 899-910.
[http://dx.doi.org/10.1080/17512433.2017.1329009] [PMID: 28490202]
[88]
Marotte H, Cimaz R. Etanercept – TNF receptor and IgG1 Fc fusion protein: is it different from other TNF blockers? Expert Opin Biol Ther 2014; 14(5): 569-72.
[http://dx.doi.org/10.1517/14712598.2014.896334] [PMID: 24611432]
[89]
Bagel J, Lynde C, Tyring S, Kricorian G, Shi Y, Klekotka P. Moderate to severe plaque psoriasis with scalp involvement: A randomized, double-blind, placebo-controlled study of etanercept. J Am Acad Dermatol 2012; 67(1): 86-92.
[http://dx.doi.org/10.1016/j.jaad.2011.07.034] [PMID: 22014541]
[90]
Gall JS, Kalb RE. Infliximab for the treatment of plaque psoriasis. Biologics 2008; 2(1): 115-24.
[PMID: 19707434]
[91]
Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56(1): 31.e1-31.e15.
[http://dx.doi.org/10.1016/j.jaad.2006.07.017] [PMID: 17097378]
[92]
Melmed GY, Targan SR, Yasothan U, Hanicq D, Kirkpatrick P. Certolizumab pegol. Nat Rev Drug Discov 2008; 7(8): 641-2.
[http://dx.doi.org/10.1038/nrd2654] [PMID: 18670430]
[93]
Papadimitriou I, Bakirtzi K, Katoulis A, Ioannides D. Scalp psoriasis and biologic agents: A review. Skin Appendage Disord 2021; 7(6): 439-48.
[http://dx.doi.org/10.1159/000517806] [PMID: 34901174]
[94]
Reich K, Ortonne JP, Gottlieb AB, et al. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: Results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol 2012; 167(1): 180-90.
[http://dx.doi.org/10.1111/j.1365-2133.2012.10941.x] [PMID: 22413944]
[95]
Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2016; 175(2): 273-86.
[http://dx.doi.org/10.1111/bjd.14493] [PMID: 26914406]
[96]
Galluzzo M, D’Adamio S, Massaro A, Piccolo A, Bianchi L, Talamonti M. Spotlight on brodalumab in the treatment of plaque psoriasis: The evidence to date. Clin Cosmet Investig Dermatol 2019; 12: 311-21.
[http://dx.doi.org/10.2147/CCID.S165605] [PMID: 31118733]
[97]
Gisondi P, Girolomoni G. Brodalumab in the treatment of chronic plaque psoriasis. Expert Opin Biol Ther 2020; 20(10): 1175-86.
[http://dx.doi.org/10.1080/14712598.2020.1776256] [PMID: 32463723]
[98]
Elewski B, Rich P, Lain E, Soung J, Lewitt GM, Jacobson A. Efficacy of brodalumab in the treatment of scalp and nail psoriasis: Results from three phase 3 trials. J Dermatolog Treat 2022; 33(1): 261-5.
[http://dx.doi.org/10.1080/09546634.2020.1749546] [PMID: 32250714]
[99]
Saeki H, Nakagawa H, Ishii T, et al. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol 2015; 29(6): 1148-55.
[http://dx.doi.org/10.1111/jdv.12773] [PMID: 25355284]
[100]
Strober B, Leonardi C, Papp KA, et al. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. J Am Acad Dermatol 2017; 76(3): 432-440.e17.
[http://dx.doi.org/10.1016/j.jaad.2016.09.026] [PMID: 27889292]
[101]
Langley RG, Rich P, Menter A, et al. Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2015; 29(9): 1763-70.
[http://dx.doi.org/10.1111/jdv.12996] [PMID: 25693783]
[102]
Berg SH, Balogh EA, Ghamrawi RI, Feldman SR. A review of secukinumab in psoriasis treatment. Immunotherapy 2021; 13(3): 201-16.
[http://dx.doi.org/10.2217/imt-2020-0195] [PMID: 33203276]
[103]
Bagel J, Nia J, Hashim PW, et al. Secukinumab is superior to ustekinumab in clearing skin in patients with moderate to severe plaque psoriasis (16-week CLARITY results). Dermatol Ther 2018; 8(4): 571-9.
[http://dx.doi.org/10.1007/s13555-018-0265-y] [PMID: 30334147]
[104]
Feldman SR, Green L, Kimball AB, et al. Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis. J Dermatolog Treat 2017; 28(8): 716-21.
[http://dx.doi.org/10.1080/09546634.2017.1329502] [PMID: 28737440]
[105]
Kivelevitch D, Amin S, Menter A. Clinical utility of secukinumab in moderate-to-severe scalp psoriasis: evidence to date. Clin Cosmet Investig Dermatol 2019; 12: 249-53.
[http://dx.doi.org/10.2147/CCID.S165040] [PMID: 31118728]
[106]
Galluzzo M, D’Adamio S, Silvaggio D, Lombardo P, Bianchi L, Talamonti M. In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis. Expert Opin Biol Ther 2020; 20(2): 173-82.
[http://dx.doi.org/10.1080/14712598.2020.1708897] [PMID: 31880166]
[107]
Paton DM. Guselkumab: Human monoclonal antibody against interleukin-23 for moderate to severe psoriasis. Drugs Today 2018; 54(3): 199-207.
[http://dx.doi.org/10.1358/dot.2018.54.3.2795155] [PMID: 29771254]
[108]
Yang EJ, Sanchez IM, Beck K, Sekhon S, Wu JJ, Bhutani T. Guselkumab for the treatment of moderate-to-severe plaque psoriasis. Expert Rev Clin Pharmacol 2018; 11(4): 333-44.
[http://dx.doi.org/10.1080/17512433.2018.1445967] [PMID: 29478344]
[109]
Sinclair R, Thirthar Palanivelu V. Tildrakizumab for the treatment of psoriasis. Expert Rev Clin Immunol 2019; 15(1): 5-12.
[http://dx.doi.org/10.1080/1744666X.2019.1544493] [PMID: 30394141]
[110]
Galluzzo M, Talamonti M, Cioni A, et al. Efficacy of tildrakizumab for the treatment of difficult-to-treat areas: Scalp, nail, palmoplantar and genital psoriasis. J Clin Med 2022; 11(9): 2631.
[http://dx.doi.org/10.3390/jcm11092631] [PMID: 35566756]
[111]
Yang K, Oak ASW, Elewski BE. Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: A comprehensive review. Am J Clin Dermatol 2021; 22(2): 173-92.
[http://dx.doi.org/10.1007/s40257-020-00578-0] [PMID: 33301128]
[112]
Camela E, Ocampo-Garza SS, Cinelli E, Villani A, Fabbrocini G, Megna M. Therapeutic update of biologics and small molecules for scalp psoriasis: A systematic review. Dermatol Ther 2021; 34(2)e14857
[http://dx.doi.org/10.1111/dth.14857] [PMID: 33559275]
[113]
Weber J, Keam SJ. Ustekinumab. BioDrugs 2009; 23(1): 53-61.
[http://dx.doi.org/10.2165/00063030-200923010-00006] [PMID: 19344192]
[114]
Papadavid E, Ferra D, Koumaki D, et al. Ustekinumab induces fast response and maintenance of very severe refractory scalp psoriasis: Results in two Greek patients from the psoriasis hospital-based clinic. Dermatology 2014; 228(2): 107-11.
[http://dx.doi.org/10.1159/000357030] [PMID: 24504077]
[115]
Welsch K, Holstein J, Laurence A, Ghoreschi K. Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors. Eur J Immunol 2017; 47(7): 1096-107.
[http://dx.doi.org/10.1002/eji.201646680] [PMID: 28555727]
[116]
Alsenaid A, Ezmerli M, Srour J, Heppt M, Illigens BM, Prinz JC. Biologics and small molecules in patients with scalp psoriasis: A systematic review. J Dermatolog Treat 2022; 33(1): 473-82.
[http://dx.doi.org/10.1080/09546634.2020.1770167] [PMID: 32406275]
[117]
Dogra S, Afra TP, Razmi TM. Apremilast in psoriasis and beyond: Big hopes on a small molecule. Indian Dermatol Online J 2019; 10(1): 1-12.
[http://dx.doi.org/10.4103/idoj.IDOJ_437_18] [PMID: 30775293]
[118]
Lé AM, Puig L, Torres T. Deucravacitinib for the treatment of psoriatic disease. Am J Clin Dermatol 2022; 23(6): 813-22.
[http://dx.doi.org/10.1007/s40257-022-00720-0] [PMID: 35960487]
[119]
Vázquez-Herrera NE, Sharma D, Aleid NM, Tosti A. Scalp itch: A systematic review. Skin Appendage Disord 2018; 4(3): 187-99.
[http://dx.doi.org/10.1159/000484354] [PMID: 30197900]
[120]
Shalaby RA, El-Gazayerly O, Abdallah M. Cubosomal betamethasone-salicylic acid nano drug delivery system for enhanced management of scalp psoriasis. Int J Nanomed 2022; 1659-77.
[http://dx.doi.org/10.2147/IJN.S345430]
[121]
Samarasekera EJ, Sawyer L, Wonderling D, Tucker R, Smith CH. Topical therapies for the treatment of plaque psoriasis: Systematic review and network meta-analyses. Br J Dermatol 2013; 168(5): 954-67.
[http://dx.doi.org/10.1111/bjd.12276] [PMID: 23413913]

Rights & Permissions Print Cite
Article Metrics
30
2
© 2024 Bentham Science Publishers | Privacy Policy